Cyclacel Pharma Initiates Phase 2 Clinical Trial of Sapacitabine In Patients With Non-Small Cell Lung Cancer
January 13th, 2009
Tuesday, Cyclacel Pharmaceuticals Inc. said it began a Phase 2, open label, single arm, multicenter clinical trial of sapacitabine in patients with non-small cell lung cancer who have had one prior chemotherapy. The study builds on the observation of prolonged stable disease of four months or longer experienced by heavily pretreated non-small cell lung cancer patients involved in two Phase 1 studies of sapacitabine.